Midline and right frontal brain function as a physiologic biomarker of remission in major depression

Psychiatry Research - Neuroimaging

Volumn 174, Issue 2, 2009, Pages 152-157

  Cook, Ian A ^a   Hunter, Aimee M ^a   Abrams, Michelle ^a   Siegman, Barbara ^a   Leuchter, Andrew F ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Biomarker; Cordance; EEG; Major depression; Neurophysiology; Remission

Indexed keywords

FLUOXETINE; PLACEBO; VENLAFAXINE;

ADULT; ARTICLE; BRAIN FUNCTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG RESPONSE; ELECTROENCEPHALOGRAPHY; FEMALE; FRONTAL CORTEX; HAMILTON SCALE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; NEUROPHYSIOLOGY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; THETA RHYTHM;

ADULT; ANALYSIS OF VARIANCE; ANTIDEPRESSIVE AGENTS; BIOLOGICAL MARKERS; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; ELECTROENCEPHALOGRAPHY; FEMALE; FRONTAL LOBE; FUNCTIONAL LATERALITY; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; RECURRENCE; ROC CURVE; SEVERITY OF ILLNESS INDEX; SPECTRUM ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 72049128608     PISSN: 09254927     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pscychresns.2009.04.011     Document Type: Article

References (67)

1. Anderer P., Saletu B., and Pascual-Marqui R.D. Effect of the 5-HT(1A) partial agonist buspirone on regional brain electrical activity in man: a functional neuroimaging study using low-resolution electromagnetic tomography (LORETA). Psychiatry Research: Neuroimaging 100 (2000) 81-96
2. Asada H., Fukuda Y., Tsunoda S., Yamaguchi M., and Tonoike M. Frontal midline theta rhythms reflect alternative activation of prefrontal cortex and anterior cingulate cortex in humans. Neuroscience Letters 274 (1999) 29-32
3. Bareš M., Brunovsky M., Kopeček M., Stopková P., Novák T., Kozeny J., and Hoschl C. Changes in QEEG prefrontal cordance as a predictor of response to antidepressants in patients with treatment resistant depressive disorder: a pilot study. Journal of Psychiatric Research 41 (2007) 319-335
4. Bareš M., Brunovsky M., Kopeček M., Novák T., Stopková P., Kozeny J., Sos P., Krajca V., and Höschl C. Early reduction in prefrontal theta QEEG cordance value predicts response to venlafaxine treatment in patients with resistant depressive disorder. European Psychiatry 23 (2008) 350-355
5. Blackhart G.C., Minnix J.A., and Kline J.P. Can EEG asymmetry patterns predict future development of anxiety and depression? A preliminary study. Biological Psychology 72 (2006) 46-50
6. Brody A.L., Barsom M.W., Bota R.G., and Saxena S. Prefrontal-subcortical and limbic circuit mediation of major depressive disorder. Seminars in Clinical Neuropsychiatry 6 (2001) 102-112
7. Cook I.A., and Leuchter A.F. Prefrontal changes and treatment response prediction in depression. Seminars in Clinical Neuropsychiatry 6 (2001) 113-120
8. Cook I.A., O'Hara R., Uijtdehaage S.H.J., Mandelkern M., and Leuchter A.F. Assessing the accuracy of topographic EEG mapping for determining local brain function. Electroencephalography and Clinical Neurophysiology 107 (1998) 408-414
9. Cook I.A., Leuchter A.F., Morgan M., Witte E., Stubbeman W.F., Abrams M., Rosenberg S., and Uijtdehaage S.H. Early changes in prefrontal activity characterize clinical responders to antidepressants. Neuropsychopharmacology 27 (2002) 120-131
10. Cook I.A., Leuchter A.F., Morgan M.L., Stubbeman W., Siegman B., and Abrams M. Changes in prefrontal activity characterize clinical response in SSRI nonresponders: a pilot study. Journal of Psychiatric Research 39 (2005) 461-466
11. Davidson R. Parsing affective space: perspectives from neuropsychology and psychophysiology. Neuropsychology 7 (1993) 464-475
12. Davidson R.J. Affective neuroscience and psychophysiology: toward a synthesis. Psychophysiology 40 (2003) 655-665
13. Davidson R.J., Pizzagalli D., Nitschke J.B., and Putnam K. Depression: perspectives from affective neuroscience. Annual Review of Psychology 53 (2002) 545-574
14. First M., Spitzer R., Gibbon M., and Williams J. Structured Clinical Interview for DSM-IV Axis I Disorders - Patient Edition. Biometrics Research Department, New York State Psychiatric Institute (1994)
15. Fitzgerald P.B., Oxley T.J., Laird A.R., Kulkarni J., Egan G.F., and Daskalakis Z.J. An analysis of functional neuroimaging studies of dorsolateral prefrontal cortical activity in depression. Psychiatry Research: Neuroimaging 148 (2006) 33-45
16. Frank E., Prien R.F., Jarrett R.B., Keller M.B., Kupfer D.J., Lavori P.W., Rush A.J., and Weissman M.M. Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. Archives of General Psychiatry 48 (1991) 851-855
17. Gotlib I.H. EEG alpha asymmetry, depression, and cognitive functioning. Cognition and Emotion 12 (1998) 449-478
18. Hjorth B. EEG analysis based on time domain properties. Electroencephalography and Clinical Neurophysiology 29 (1970) 306-310
19. Hjorth B. An on-line transformation of EEG scalp potentials into orthogonal source derivations. Electroencephalography and Clinical Neurophysiology 39 (1975) 526-530
20. Hunter A.M., Leuchter A.F., Morgan M.L., Cook I.A., Abrams M., Siegman B., DeBrota D.J., and Potter W.Z. Neurophysiologic correlates of side effects in normal subjects randomized to venlafaxine or placebo. Neuropsychopharmacology 30 (2005) 792-799
21. Hunter A.M., Leuchter A.F., Morgan M.L., and Cook I.A. Changes in brain function (quantitative EEG cordance) during placebo lead-in and treatment outcomes in clinical trials for major depression. American Journal of Psychiatry 163 (2006) 1426-1432
22. Hunter A.M., Ravikumar S., Cook I.A., and Leuchter A.F. Brain functional changes during placebo lead-in and changes in specific symptoms during pharmacotherapy for major depression. Acta Psychiatrica Scandinavica 119 (2009) 266-273
23. Ishii R., Shinosaki K., Ukai S., Inouye T., Ishihara T., Yoshimine T., Hirabuki N., Asada H., Kihara T., Robinson S.E., and Takeda M. Medial prefrontal cortex generates frontal midline theta rhythm. Neuroreport 10 (1999) 675-679
24. Judd L.L., Akiskal H.S., Maser J.D., Zeller P.J., Endicott J., Coryell W., Paulus M.P., Kunovac J.L., Leon A.C., Mueller T.I., Rice J.A., and Keller M.B. Major depressive disorder: a prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse. Journal of Affective Disorders 50 (1998) 97-108
25. Keller M.B. Remission versus response: the new gold standard of antidepressant care. Journal of Clinical Psychiatry 65 Suppl 4 (2004) 53-59
26. Kim S.J., Song S.H., Kim J.H., and Kwak I.S. Statistical parametric mapping analysis of the relationship between regional cerebral blood flow and symptom clusters of the depressive mood in patients with pre-dialytic chronic kidney disease. Annals of Nuclear Medicine 22 (2008) 201-206
27. Kline J.P., and Allen S. The failed repressor: EEG asymmetry as a moderator of the relation between defensiveness and depressive symptoms. International Journal of Psychophysiology 68 (2008) 228-234
28. Knott V.J., and Lapierre Y.D. Computerized EEG correlates of depression and antidepressant treatment. Progress in Neuropsychopharmacology and Biological Psychiatry 11 (1987) 213-221
29. Knott V.J., Telner J.I., Lapierre Y.D., Browne M., and Horn E.R. Quantitative EEG in the prediction of antidepressant response to imipramine. Journal of Affective Disorders 39 (1996) 175-184
30. Knott V., Mahoney C., Kennedy S., and Evans K. Pre-treatment EEG and its relationship to depression severity and paroxetine treatment outcome. Pharmacopsychiatry 33 (2000) 201-205
31. Knott V., Mahoney C., Kennedy S., and Evans K. EEG power, frequency, asymmetry and coherence in male depression. Psychiatry Research 106 (2001) 123-140
32. Knott V., Mahoney C., Kennedy S., and Evans K. EEG correlates of acute and chronic paroxetine treatment in depression. Journal of Affective Disorders 69 (2002) 241-249
33. Kopeček M., Bareš M., Brunovsky M., Stopková P., Novák T., Kozeny J., and Höschl C. EEG cordance as a predictor of response to antidepressive medication - pooled analysis. 14th European Congress of Psychiatry, AEP, March 2006, Nice, France (2006)
34. Kopeček M., Sos P., Brunovsky M., Bareš M., Stopková P., and Krajca V. Can prefrontal theta cordance differentiate between depression recovery and dissimulation?. Neuro Endocrinology Letters 28 (2007) 524-526
35. Kopeček M., Tislerova B., Sos P., Bareš M., Novak T., Krajca V., and Brunovsky M. QEEG changes during switch from depression to hypomania/mania: a case report. Neuro Endocrinology Letters 29 (2008) 295-302
36. Leuchter A.F., Uijtdehaage S.H., Cook I.A., O'Hara R., and Mandelkern M. Relationship between brain electrical activity and cortical perfusion in normal subjects. Psychiatry Research: Neuroimaging 90 (1999) 125-140
37. Leuchter A.F., Cook I.A., Witte E.A., Morgan M., and Abrams M. Changes in brain function of depressed subjects during treatment with placebo. American Journal of Psychiatry 159 (2002) 122-129
38. Leuchter A.F., Morgan M., Cook I.A., Dunkin J., Abrams M., and Witte E. Pretreatment neurophysiological and clinical characteristics of placebo responders in treatment trials for major depression. Psychopharmacology (Berlin) 177 (2004) 15-22
39. Leuchter A.F., Cook I.A., DeBrota D.J., Hunter A.M., Potter W.Z., McGrouther C.C., Morgan M.L., Abrams M., and Siegman B. Changes in brain function during administration of venlafaxine or placebo to normal subjects. Clinical EEG and Neuroscience 39 (2008) 175-181
40. Mayberg H.S., Brannan S.K., Tekell J.L., Silva J.A., Mahurin R.K., McGinnis S., and Jerabek P.A. Regional metabolic effects of fluoxetine in major depression: serial changes and relationship to clinical response. Biological Psychiatry 48 (2000) 830-843
41. Miller I.W., Keitner G.I., Schatzberg A.F., Klein D.N., Thase M.E., Rush A.J., Markowitz J.C., Schlager D.S., Kornstein S.G., Davis S.M., Harrison W.M., and Keller M.B. The treatment of chronic depression, part 3: psychosocial functioning before and after treatment with sertraline or imipramine. Journal of Clinical Psychiatry 59 (1998) 608-619
42. Milligan G.W., and Cooper M.C. Methodological review: clustering methods. Applied Psychological Measurement 11 (1987) 329-354
43. Mirkin B. Mathematical Classification and Clustering (1996), Kluwer Academic Publishers, Dordrecht
44. Mojena R. Hierarchical grouping methods and stopping rules: an evaluation. Computer Journal 20 (1977) 359-363
45. Mojtabai R. Residual symptoms and impairment in major depression in the community. American Journal of Psychiatry 158 (2001) 1645-1651
46. Morgan M.L., Cook I.A., Rapkin A.J., and Leuchter A.F. Neurophysiologic changes during estrogen augmentation in perimenopausal depression. Maturitas 56 (2007) 54-60
47. Nierenberg A.A., and Wright E.C. Evolution of remission as the new standard in the treatment of depression. Journal of Clinical Psychiatry 60 Suppl 22 (1999) 7-11
48. Ormel J., Oldehinkel A.J., Nolen W.A., and Vollebergh W. Psychosocial disability before, during, and after a major depressive episode: a 3-wave population-based study of state, scar, and trait effects. Archives of General Psychiatry 61 (2004) 387-392
49. Papakostas G.I., Petersen T., Denninger J.W., Tossani E., Pava J.A., Alpert J.E., Nierenberg A.A., and Fava M. Psychosocial functioning during the treatment of major depressive disorder with fluoxetine. Journal of Clinical Psychopharmacology 24 (2004) 507-511
50. Paykel E.S., Ramana R., Cooper Z., Hayhurst H., Kerr J., and Barocka A. Residual symptoms after partial remission: an important outcome in depression. Psychological Medicine 25 (1995) 1171-1180
51. Phillips M.L., Drevets W.C., Rauch S.L., and Lane R. Neurobiology of emotion perception II: implications for major psychiatric disorders. Biological Psychiatry 54 (2003) 515-528
52. Pizzagalli D., Pascual-Marqui R.D., Nitschke J.B., Oakes T.R., Larson C.L., Abercrombie H.C., Schaefer S.M., Koger J.V., Benca R.M., and Davidson R.J. Anterior cingulate activity as a predictor of degree of treatment response in major depression: evidence from brain electrical tomography analysis. American Journal of Psychiatry 158 (2001) 405-415
53. Rogers M.A., Kasai K., Koji M., Fukuda R., Iwanami A., Nakagome K., Fukuda M., and Kato N. Executive and prefrontal dysfunction in unipolar depression: a review of neuropsychological and imaging evidence. Neuroscience Research 50 (2004) 1-11
54. Rush A.J., Rago W.V., Crismon M.L., Toprac M.G., Shon S.P., Suppes T., Miller A.L., Trivedi M.H., Swann A.C., Biggs M.M., Shores-Wilson K., Kashner T.M., Pigott T., Chiles J.A., Gilbert D.A., and Altshuler K.Z. Medication treatment for the severely and persistently mentally ill: the Texas Medication Algorithm Project. Journal of Clinical Psychiatry 60 (1999) 284-291
55. Rush A.J., Trivedi M.H., Ibrahim H.M., Carmody T.J., Arnow B., Klein D.N., Markowitz J.C., Ninan P.T., Kornstein S., Manber R., Thase M.E., Kocsis J.H., and Keller M.B. The 16-item Quick Inventory of Depressive Symptomatology (QIDS) Clinician Rating (QIDS-C) and Self-Report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biological Psychiatry 54 (2003) 573-583
56. Rush A.J., Trivedi M.H., Wisniewski S.R., Stewart J.W., Nierenberg A.A., Thase M.E., Ritz L., Biggs M.M., Warden D., Luther J.F., Shores-Wilson K., Niederehe G., Fava M., and STAR*D Study Team. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. New England Journal of Medicine 354 (2006) 1231-1242
57. Schmidt L.A. Frontal brain electrical activity in shyness and sociability. Psychological Science 10 (1999) 316-320
58. Stubbeman W.F., Leuchter A.F., Cook I.A., Shurman B.D., Morgan M., Gunay I., and Gonzalez S. Pretreatment neurophysiologic function and ECT response in depression. Journal of ECT 20 (2004) 142-144
59. Trivedi M.H., Kern J.K., Baker S.M., and Altshuler K.Z. Computerizing medication algorithms and decision support systems for major psychiatric disorders. Journal of Psychiatric Practice 6 (2000) 237-246
60. Trivedi M.H., Rush A.J., Wisniewski S.R., Nierenberg A.A., Warden D., Ritz L., Norquist G., Howland R.H., Lebowitz B., McGrath P.J., Shores-Wilson K., Biggs M.M., Balasubramani G.K., Fava M., and STAR*D Study Team. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. American Journal of Psychiatry 163 (2006) 28-40
61. Trivedi M.H., Fava M., Wisniewski S.R., Thase M.E., Quitkin F., Warden D., Ritz L., Nierenberg A.A., Lebowitz B.D., Biggs M.M., Luther J.F., Shores-Wilson K., Rush A.J., and STAR*D Study Team. Medication augmentation after the failure of SSRIs for depression. New England Journal of Medicine 354 (2006) 1243-1252
62. Ulrich G., Haug H., Stieglitz R., and Fahndrich E. Are there distinct biochemical subtypes of depression? EEG characteristics of clinically defined on-drug responders and non-responders. Journal of Affective Disorders 15 (1988) 181-185
63. Ulrich G., Haug H.J., Stieglitz R.D., and Fahndrich E. EEG characteristics of clinically defined on-drug-responders and non-responders-a comparison clomipramine vs. maprotiline. Pharmacopsychiatry 21 (1988) 367-368
64. Ulrich G., Haug H.J., and Fahndrich E. Acute versus chronic EEG effects of maprotiline- and in clomipramine-treated depressive inpatients and the prediction of therapeutic outcome. Journal of Affective Disorders 32 (1994) 213-217
65. Vos T., Haby M.M., Barendregt J.J., Kruijshaar M., Corry J., and Andrews G. The burden of major depression avoidable by longer-term treatment strategies. Archives of General Psychiatry 61 (2004) 1097-1103
66. Warwick J.M., Carey P., Jordaan G.P., Dupont P., and Stein D.J. Resting brain perfusion in social anxiety disorder: a voxel-wise whole brain comparison with healthy control subjects. Progress in Neuropsychopharmacology and Biological Psychiatry 32 (2008) 1251-1256
67. Zimmerman M., Posternak M.A., and Chelminski I. Heterogeneity among depressed outpatients considered to be in remission. Comprehensive Psychiatry 48 (2007) 113-117